Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Mesoblast reported Ryoncil net revenue of US$36 million for the fourth quarter and US$115 million for the full fiscal year ended June 30, 2026. CEO Dr. Silviu Itescu noted strong uptake since launch, with revenues already exceeding initial projections. Management anticipates continued revenue growth in the coming fiscal year, citing momentum across major U.S.
Key figures
- Ryoncil fy revenue
- 115000000
- Ryoncil q4 revenue
- 36000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.